{
    "clinical_study": {
        "@rank": "82266", 
        "arm_group": [
            {
                "arm_group_label": "NH004 tropicamide", 
                "arm_group_type": "Experimental", 
                "description": "tropicamide 1 mg thin film, twice daily for 7 days"
            }, 
            {
                "arm_group_label": "NH004 placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo thin film, twice daily for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To study the safety and efficacy of tropicamide 1 mg intra-oral slow dissolving\n      muco-adhesive thin films compared to placebo to reduce hypersalivation in PD patients\n      manifesting sialorrhea complaints."
        }, 
        "brief_title": "Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Sialorrhea (Excessive Drooling)", 
        "condition_browse": {
            "mesh_term": "Sialorrhea"
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, placebo-controlled, randomized, crossover, multicentre study\n      comparing intra-oral slow dissolving muco-adhesive thin films containing tropicamide 1 mg or\n      Placebo. Patients will receive each treatment twice daily (1 h after breakfast and 1 h after\n      lunch) for 1-week.\n\n      Patients will be evaluated for eligibility during the 14-day screening period. Those\n      patients meeting all entry criteria at baseline will be randomized (1:1) to receive first\n      tropicamide followed by placebo films or vice versa. Patients will return for regularly\n      scheduled visits at Weeks 1 and 3 or at early discontinuation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients with idiopathic Parkinson's disease, according to the UK Brain Bank\n             criteria.\n\n          -  Patients complaining of drooling, with a score of at least 6 points in the SCS-PD\n             scale.\n\n          -  Patients above 30 years old.\n\n          -  Patients with Hoehn & Yahr score between I-IV.\n\n          -  Male or non-pregnant female. Females of child-bearing potential will be required to\n             have undergone a pregnancy test with negative results prior to entry to the study and\n             agree to use contraceptive measures for the duration of the study.\n\n          -  Patients must have used the same antiparkinsonian medications and at the same dose\n             for the last month. No changes in the medication for PD are expected during the\n             study.\n\n        Exclusion criteria:\n\n          -  Pregnant women.\n\n          -  Patients with a secondary parkinsonian syndrome, parkinsonism-plus syndromes,\n             heredodegenerative disorders or benign parkinsonism.\n\n          -  Patients with a diagnosis of major depression or psychosis according to the DSM-IV.\n\n          -  Patients with MMSE score equal to or lower than 24.\n\n          -  Patients with a current diagnosis of substance abuse (DSM-IV) or history of alcohol\n             or drug abuse in the past 3 months.\n\n          -  Patients with hallucinations.\n\n          -  Patients with a current clinically significant gastrointestinal, renal, hepatic,\n             endocrine, pulmonary or cardiovascular disease, including hypertension that is not\n             well-controlled, asthma, chronic obstructive pulmonary disease (COPD) and Type I\n             diabetes.\n\n          -  Patients with a second- or third-degree atrioventricular block or sick sinus\n             syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive\n             heart failure, myocardial infarction within 3 months of the screening visit, or\n             significant ECG abnormality, including QTc \u2265 450 msec (males) or \u2265 470 msec\n             (females), where QTc is based on Bazett's correction method.\n\n          -  Patient with a neoplastic disorder, which is either currently active or has been in\n             remission for less than one year.\n\n          -  Patients with a history or a current diagnosis of HIV, or tests positive for\n             Hepatitis B or C antibodies, or Hepatitis B surface antigen\n\n          -  Patients who have participated in a previous clinical trial within 30 days of entry\n             into the study (screening visit) or have received treatment with any investigational\n             compound within 30 days.\n\n          -  Patients with hypersensitivity to atropine or other anticholinergic drugs.\n\n          -  Patients who have experienced adverse effects as a result of taking anticholinergic\n             drugs.\n\n          -  Patients who are receiving any anticholinergic drug or an anticholinesterase agent.\n\n          -  Patients who started or changed the dose of any of the following medications in the\n             previous week: tricyclic antidepressants, monoamine oxidase-A inhibitors,\n             antipsychotics, benzodiazepines, opioids, antihistamines, carbamazepine, NSAIDs.\n\n          -  Patients with significant dental/oral pathology.\n\n          -  Patient with any abnormality that the investigator deems to be clinically relevant,\n             either on medical history, physical examination, ECG or in a diagnostic laboratory\n             test.\n\n          -  Patients with closed-angle Glaucoma or those at high risk of suffering it after\n             treatment with anticholinergic agents.\n\n          -  Patients with Prostatic Adenoma.\n\n          -  In the judgment of the Clinical Investigator, the patient is likely to be\n             non-compliant or uncooperative during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844648", 
            "org_study_id": "NH004-3", 
            "secondary_id": "2011-004212-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "NH004 tropicamide", 
                "description": "Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide", 
                "intervention_name": "NH004 tropicamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NH004 placebo", 
                "description": "Intra-oral slow dissolving muco-adhesive thin film", 
                "intervention_name": "NH004 Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tropicamide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Parkinson's disease", 
            "Sialorrhea", 
            "Tropicamide", 
            "Non-motor symptoms", 
            "Thin strip delivery"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tec1.cet@psl.aphp.fr", 
                    "last_name": "Stephanie Lejeune"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "Cedrex 13", 
                        "zip": "75651"
                    }, 
                    "name": "H\u00f4pital de la Salp\u00eatri\u00e8re"
                }, 
                "investigator": {
                    "last_name": "Marie Vidailhet, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pascale.gauteul@inserm.fr", 
                    "last_name": "Pascale Gauteul"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "state": "Cedrex 9", 
                        "zip": "31059"
                    }, 
                    "name": "H\u00f4pital Paul de Viguier"
                }, 
                "investigator": {
                    "last_name": "Olivier Rascoll, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "morgane.gaboreau@chu-bordeaux.fr", 
                    "last_name": "Morgane Gaboreau"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "state": "Pessac", 
                        "zip": "33604"
                    }, 
                    "name": "H\u00f4pital Haut L\u00e9v\u00eaque"
                }, 
                "investigator": {
                    "last_name": "Francois Tison, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Safety and Efficacy of Tropicamide 1 mg Intra-oral Slow Dissolving Muco-adhesive Thin Films to Reduce Hypersalivation in PD Patients Manifesting Sialorrhea Complaints", 
        "overall_contact": {
            "email": "elkan@neurohealing.com", 
            "last_name": "Elkan R Gamzu, PhD", 
            "phone": "6179652680"
        }, 
        "overall_official": {
            "affiliation": "NeuroHealing Pharmaceuticals Inc.", 
            "last_name": "Elkan R Gamzu, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint for this trial is the difference in responder rate between tropicamide and placebo. Responders will be defined as subjects whose mean sialorrhea score improved by at least 30% as compared to baseline in the 9-point modified Teachers Drooling Scale (mTDS).", 
            "measure": "modified Teachers Drooling Scale (% responding)", 
            "safety_issue": "No", 
            "time_frame": "one week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844648"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference in the mean sialorrhea scores between placebo and tropicamide in the 9-point modified Teachers Drooling Scale (mTDS).", 
                "measure": "modified Teachers Drooling Scale (mean)", 
                "safety_issue": "No", 
                "time_frame": "one week"
            }, 
            {
                "description": "- Difference in the mean sialorrhea scores between placebo and tropicamide in the Sialorrhea Clinical Scale for Parkinson's Disease (SCS-PD).", 
                "measure": "Sialorrhea Clinical Scale for Parkinson's Disease (mean)", 
                "safety_issue": "No", 
                "time_frame": "one week"
            }, 
            {
                "description": "Difference in the mean sialorrhea scores between placebo and tropicamide in the UPDRS Part II sialorrhea item (#6).", 
                "measure": "UPDRS Part II sialorrhea item (mean)", 
                "safety_issue": "No", 
                "time_frame": "one week"
            }, 
            {
                "description": "Saliva buccal content as measured by a Visual Analog Scale (VAS) score, evaluated before and during 3 hours after treatments administration.", 
                "measure": "Visual Analg Scale", 
                "safety_issue": "No", 
                "time_frame": "one week"
            }
        ], 
        "source": "NeuroHealing Pharmaceuticals Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Michael J. Fox Foundation for Parkinson's Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "NeuroHealing Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}